Nanoparticle-decorated cells power novel approach to cancer therapy

September 17, 2010

Clinical trials using patients' own immune cells to target tumors have yielded promising results. However, this approach usually works only when patients also receive large doses of drugs designed to help immune cells multiply rapidly, and those drugs have life-threatening side effects. Now a team of MIT engineers has devised a way to deliver the necessary drugs by smuggling them within nanoparticles that are attached to the cells sent in to fight the tumor. As a result, the immune cell stimulating drug reaches only its intended targets, greatly reducing the risk to the patient.

The new approach could dramatically improve the success rate of immune-cell therapies, which hold promise for treating many types of cancer, says Darrell Irvine. Dr. Irvine led the team that published its results in the journal Nature Medicine. "What we're looking for is the extra nudge that could take immune-cell therapy from working in a subset of people to working in nearly all patients, and to take us closer to cures of disease rather than slowing progression," said Dr. Irvine. The new method could also be used to deliver other types of or to promote blood-cell maturation in transplant recipients, according to the researchers.

To perform immune-cell therapy, doctors remove a type of immune cell called T cells from the patient, engineer them to target the tumor, and inject them back into the patient. Those T cells then hunt down and destroy . Clinical trials are under way in which immune-cell therapy is being tested in patients with ovarian and prostate cancers, as well as .

Immune-cell therapy is a very promising approach to treating cancer, but getting it to work has proved challenging. The major limitations today include procuring enough of the T cells that are specific to the cancer cell and then getting those T cells to function properly in the patient. To overcome those obstacles, researchers have tried injecting patients with adjuvant drugs that stimulate T-cell growth and proliferation. The interleukins—naturally occurring chemicals that help promote T-cell growth—have produced promising results in human clinical trials, but interleukin therapy can produce severe side effects, including heart and lung failure, when infused into the blood stream in large doses.

Dr. Irvine and his colleagues took a new approach: To avoid toxic side effects, they turned to lipid-based nanoparticles that they can attach to sulfur-containing molecules normally found on the T-cell surface. The investigators loaded two interleukins - IL-15 and IL-21 - into the nanoparticles, and then injected the nanoparticle-T cell combo into mice with lung and bone marrow tumors. Once the cells reached the tumors, the nanoparticles gradually degraded and released the drug over a week-long period. The drug molecules attached themselves to receptors on the surface of the same cells that carried them, stimulating them to grow and divide.

Within 16 days, all of the tumors in the mice treated with T cells carrying the drugs disappeared. Those mice survived until the end of the 100-day experiment, while mice that received no treatment died within 25 days, and mice that received either T cells alone or with injections of interleukins died within 75 days.

Dr. Irvine and his colleagues also demonstrated that they could attach their nanoparticles to the surface of immature blood cells found in the bone marrow, which are commonly used to treat leukemia. Patients who receive bone-marrow transplants must have their own bone marrow destroyed with radiation or chemotherapy before the transplant, which leaves them vulnerable to infection for about six months while the new bone marrow produces blood cells. Delivering drugs that accelerate blood-cell production along with the bone-marrow transplant could shorten the period of immunosuppression, making the process safer for patients, says Dr. Irvine. In the Nature Medicine paper, his team reports successfully enhancing blood-cell maturation in mice by delivering one such drug along with the cells.

This work, which was supported in part by the National Cancer Institute, is detailed in a paper titled, "Therapeutic cell engineering with surface-conjugated synthetic ." An abstract is available at the journal's Web site.

Explore further: Drugs encased in nanoparticles travel to tumors on the surface of immune-system cells

Related Stories

Molecule dictates how stem cells travel

January 14, 2006

U.S. researchers have defined a molecule that dictates how blood stem cells travel to the bone marrow and establish blood and immune cell production.

Drug/radiation combo may help shrink established tumors

August 25, 2008

Researchers may be closer to understanding why anti-cancer drugs such as Ipilimumab, which boost the tumor-killing power of immune cells, haven't fared well in clinical trials. The new study, which describes a way to enhance ...

Recommended for you

Clothing fabric keeps you cool in the heat

November 16, 2017

(—Researchers have designed a thermal regulation textile that has a 55% greater cooling effect than cotton, which translates to cooler skin temperatures when wearing clothes made of the new fabric. The material ...

Semiconductors with an aligned interface

November 13, 2017

The electronic characteristics of an interface between two wide bandgap semiconductors are determined by researchers at KAUST: an insight that will help improve the efficiency of light-emitting and high-power electronic devices.

Zipping DNA

November 13, 2017

ETH researchers have developed a method that allows large amounts of genetic information to be compressed and then decompressed again in cells. This could aid in the development of new therapies.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.